Folison

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Folison

What is Folison? Definition and Purpose

Property Description
Active Ingredient L-Methylfolate (5-MTHF)
Form Oral Tablet or Capsule
Pharmacological Class B-Vitamin Analog / Essential Nutrient Supplement
Common Purpose Supports active folate levels for nerve and metabolic health
Origin Synthetic/Pharmaceutical Grade

Folison is a therapeutic preparation containing the active ingredient L-Methylfolate, the official International Nonproprietary Name (INN) for the reduced and biologically active form of Vitamin B9. It is classified as an Essential Nutrient Supplement that is clinically recognized for its high bioavailability, bypassing the metabolic steps required to convert standard Folic Acid into its usable form.

This specific formulation is designed to ensure the nutrient can readily cross the blood-brain barrier, making L-Methylfolate crucial for the central nervous system. The compound supports the biosynthesis of essential neurotransmitters like serotonin and dopamine, providing a necessary building block for supporting cognitive function and mood health.

Composition and Origin: Is Folison Natural or Synthetic?

Folison is typically delivered as an oral tablet or capsule containing the purified L-Methylfolate compound, which is primarily obtained through a controlled synthetic process. While the nutrient occurs naturally in foods, the medicine is synthesized to ensure pharmaceutical purity, stability, and precise therapeutic dosing, a key differentiating factor from simple dietary supplements.

Pharmacological studies have supported the role of L-Methylfolate in regulating the cycle that converts homocysteine to methionine, a process vital for cardiovascular and neurological health. This confirms the medicine's role in supporting general metabolic balance in individuals who require the active form of the nutrient for efficient utilization.

General Therapeutic Purpose

The general therapeutic purpose of Folison is to optimize and maintain functional levels of active folate in the body. It is used to provide robust nutritional support by managing deficiencies or metabolic impairments related to folate conversion, thereby supporting overall cellular function and systemic well-being.

Regulatory References

  1. NIH Fact Sheet on Folate
  2. MedlinePlus Folate Information

What side effects are possible with Folison?

Possible Side Effects and Safety Information

Regulatory safety documents classify the adverse effects of Folison (L-Methylfolate) primarily by the affected physiological system, though frequency is often not defined using standard terms like 'common' or 'uncommon'. Most reported reactions tend to be minor and transient.


Adverse Reaction Categories

System-Organ Class Examples of Documented Adverse Reactions
Gastrointestinal Nausea, flatulence, abdominal distention, anorexia, and diarrhea
Nervous System Transient headaches, somnolence, altered sleep patterns, irritability, and difficulty concentrating
Immune System/Skin Manifestations of hypersensitivity, including rash, itching, and signs of allergic reaction

Serious Safety Constraints

Government regulatory information highlights two primary areas of serious concern. The potential for severe hypersensitivity or allergic reaction (including swelling and difficulty breathing) is a serious adverse reaction noted in the label. Furthermore, caution is necessary regarding the theoretical risk of activating underlying psychiatric conditions, such as a manic state, particularly upon initiation of treatment.

Critical Safety Limitation

Folison's active ingredient is subject to a critical safety limitation: its use may mask the hematological signs of an existing Vitamin B12 deficiency (pernicious anemia). If this deficiency remains undiagnosed and untreated, irreversible neurological damage can progress. Official documents require this constraint to be addressed.

Population-Specific Notes: Dose adjustment is not generally necessary for individuals with renal or hepatic impairment. Caution is advised for children and adolescents regarding observation for symptoms of psychiatric disorder activation.

Overdose and Emergency Response

The official regulatory profile for Folison (L-Methylfolate) indicates that an acute overdose is unlikely to cause life-threatening symptoms. As an essential nutrient, the most critical concern documented by regulatory authorities is the potential for high doses to mask the signs of Vitamin B12 deficiency. This masking effect is a severe, officially recognized risk that can allow progressive and irreversible neurological damage to continue undetected.

Category Officially Documented Information
Overdose Manifestations Symptoms may include gastrointestinal distress (nausea, vomiting, stomach pain) and central nervous system effects such as irritability or disturbed sleep.
Emergency Action Required Seek medical help immediately or contact Poison Control following any suspected overdose. Emergency services must be called if the patient experiences serious symptoms like passing out or difficulty breathing.

Overdose management, as defined in regulatory documents, is symptomatic and supportive, as no specific antidote is known for L-Methylfolate. Monitoring of Vitamin B12 levels may be required. Furthermore, a specific regulatory warning exists concerning the risk of accidental fatal poisoning in children younger than 6 years for oral tablets containing folate.

Therapeutic Uses of Folison

Folison, which provides the active ingredient L-Methylfolate, is generally used to provide supportive symptomatic relief in situations involving systemic imbalance. It is applied across domains where additional symptomatic support is needed, such as in the context of persistent low mood or when managing symptoms related to systemic imbalance.


Adjunctive Support for Lingering Mood Symptoms

This medication is applied in addressing symptom clusters that may become intense or disruptive, such as persistent low mood and apathy, which often occur in conditions involving episodic or fluctuating manifestations. This supportive use may assist patients with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.

Managing Systemic Metabolic and Cognitive Deficits

Folison is relevant for easing symptoms that may intensify temporarily in conditions marked by increased physiological stress, especially in patient groups with genetic variations that affect folate conversion. It is commonly used to help with managing symptoms related to systemic functional stress and contributes to improved comfort during periods of heightened symptoms. It may assist with managing symptoms that interfere with daily functioning, such as difficulty with focus and mental clarity.


Quick Fact: Relief for Residual Symptoms
Folison is used when groups of symptoms appear suddenly or fluctuate, and provides support that helps ease the overall symptom burden.

Regulatory References

  1. NIH DailyMed entry for L-METHYLFOLATE CALCIUM Tablets

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Folison — Official Regulatory Information

This section describes the official regulatory criteria for who can and cannot use Folison (folic acid), strictly based on governmental documentation.


Contraindications (Must Not Use)

Folison is contraindicated and must not be used in the following populations:

  • Patients with known hypersensitivity to folic acid or any excipients.
  • Individuals with malignant disease, unless the accompanying megaloblastic anaemia is specifically caused by folic acid deficiency.
  • Patients with pernicious anaemia or undiagnosed megaloblastic anaemia where Vitamin B12 deficiency has not been ruled out. Using Folison alone in these cases is prohibited due to the risk of irreversible neurological deterioration.
  • Individuals with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (due to the presence of lactose excipients).

Populations Requiring Special Consideration

  • Undiagnosed Megaloblastic Anaemia: The cause of anaemia must be elucidated before initiating treatment to ensure Vitamin B12 deficiency is managed concurrently, if present.
  • Folate-Dependent Tumours: Use in these patients requires caution.
  • Elderly Patients: A cobalamin absorption test is recommended before starting long-term folate therapy.
  • Pregnancy and Lactation: Use is generally allowed and indicated for megaloblastic anaemia during pregnancy; no adverse effects have been observed in breast-fed infants.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Folison (L-Methylfolate) is structured around two primary interaction types: modifications to plasma levels and pharmacodynamic conflicts with antifolate agents. A formal regulatory constraint is the contraindication for patients with known hypersensitivity to any component of the product.

Folison may decrease the plasma concentration of certain Anticonvulsants, including phenytoin, carbamazepine, and primidone. Conversely, several agents, such as Cholestyramine, Colestipol, and Sulfasalazine, are documented to decrease the serum concentration of L-Methylfolate, potentially through reduced absorption.

Regarding pharmacodynamic effects, co-administration with Antifolate Agents like methotrexate, pyrimethamine, and trimethoprim may be subject to therapeutic conflict. Folison may increase the risk or severity of adverse effects (toxicity) when combined with certain fluoropyrimidine chemotherapy agents, such as Fluorouracil and Capecitabine. The regulatory documents also note that co-administration with Raltitrexed is an avoided combination.

Lifestyle substances are also cited, as chronic alcohol consumption and smoking are associated with reduced serum folate levels. The interaction affecting anticonvulsant plasma levels is of potentially greater clinical significance in pediatric populations, which is a noted population-specific consideration.

Mechanism of Action

Core Cofactor Function and DNA Synthesis

Folison acts as an essential metabolic cofactor, supplying the necessary single-carbon units required by cellular enzymes like Thymidylate Synthase to synthesize the building blocks for DNA and RNA. This fundamental molecular action provides the metabolic basis for cellular replication, repair, and maturation in high-turnover tissues.


Regulation of the Methionine Cycle

The mechanism of Folison is directly coupled to the Methionine Cycle, supporting the production of S-adenosylmethionine (SAM). SAM is the body's universal methyl donor. This process is relevant for functions that rely on epigenetic regulation (gene expression). The synthesis of key neurotransmitters and the engagement of epigenetic regulation influence systemic physiological function.

Dosage and Administration Information

How Folison is Used: Official Administration Guidelines

Folison (L-Methylfolate) is utilized according to a standardized protocol for the dietary management of related metabolic deficits. The overall use pattern is based on a continuous, long-term administration model, consistent with its classification as an essential nutrient analog.


Official Dosing and Administration

Administration Scope Procedural Detail
Route of Administration Oral
Dosing Schedule Once daily, utilizing either the 7.5 mg or 15 mg strength.
Dosing Limit The dose should not exceed 40 mg/ day in patients with moderate-to-severe renal or hepatic impairment.
Intake Conditions The tablets may be taken with or without food.

Usage Context and Procedural Constraints

The formal usage protocol for Folison defines specific conditions for proper administration. The tablets are intended for consumption in their oral form and are required to be administered under medical supervision.

A key procedural constraint is the status of coexisting deficiencies: Folison therapy alone is specified as inadequate for use as the sole treatment in the setting of Vitamin B12 deficiency. Established guidelines require that the status of B12 must be concurrently addressed. Furthermore, safety and efficacy have not been established for use in patients under 18 years of age.

This structured approach ensures the medicine is utilized consistently within defined parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Folison


Evidence for Adjunctive Support in Persistent Low Mood Symptoms

Research on Folison (L-Methylfolate) has primarily been conducted using short-term, randomized, placebo-controlled trials (RCTs). These studies were used in research exploring how symptoms change over time when Folison was studied as an add-on treatment alongside ongoing standard antidepressant therapy. The studies included adults who were already taking prescribed medication for low mood and whose symptoms were still being explored by researchers. Study data reported varying rates of change in symptom scores and attainment of response thresholds in the group receiving Folison. Research monitored different groups, including those defined by certain genetic variations that relate to how the body processes folate. Evidence contributes to understanding symptom patterns, particularly for individuals relevant for studies of the active form of Vitamin B9. However, the reported outcomes were short-term and based on small populations within these controlled settings.

Evidence for Systemic Metabolic and Cognitive Support

Folison was also evaluated in research examining temporary physiological imbalance and systemic health. This research primarily focused on biochemical outcomes rather than direct symptoms. Studies explored how L-Methylfolate affects the body's folate levels and measured changes in homocysteine, a biomarker that reflects systemic or functional imbalance. Research highlights changes measured during the study period, showing that the use of L-Methylfolate was observed in some studies to be associated with measurable increases in active folate levels and patterns of change in homocysteine levels. Findings related to patient-reported outcomes describing perceived discomfort or functional status were generally small and varied, particularly in settings not involving specific genetic or metabolic risk factors.

Research Gaps and What is Still Under Investigation

Scientific literature indicates several areas where research remains insufficient. Long-term effects are not fully established regarding the use of Folison, as the follow-up durations were limited in the most rigorous short-term trials. Comparative evidence is lacking, meaning that high-quality studies comparing Folison against other similar nutritional approaches are being explored. Data are still emerging regarding its study in specific groups; for instance, there is limited information from studies that included children or pregnant individuals. Evidence highlights what is known—and what is still uncertain.

Key Studies & References

  1. L-METHYLFOLATE CALCIUM Tablets (Deplin) - Official FDA/DailyMed Labeling
  2. Meta-Analysis of L-Methylfolate as Adjunctive Therapy for Major Depressive Disorder
  3. NIH MedlinePlus Drug Information: L-Methylfolate

Frequently Asked Questions (FAQ)

Common questions about Folison (FAQ)


Q: Why do some people refer to Folison as a 'vitamin' instead of a drug?

A: Folison contains L-Methylfolate, which is the active and readily usable form of Vitamin B9. Because of this, it is sometimes informally called a vitamin. Official documents classify Folison as a B-Vitamin Analog or Essential Nutrient Supplement, or in some cases, a Medical Food, reflecting its role in providing a specialized, essential nutrient.


Q: Can Folison be used by people with lactose intolerance?

A: Some formulations of Folison contain lactose excipients (inactive ingredients). Official regulatory documents specify that the product is contraindicated (meaning its use is advised against) in individuals with rare hereditary problems like galactose intolerance or Lapp lactase deficiency because of the presence of this ingredient.


Q: How long does it typically take to start noticing an effect from Folison?

A: Regulatory data on the active ingredient, L-Methylfolate, indicate that it has a relatively short elimination half-life from the bloodstream. However, the substance is naturally stored in red blood cells, where official information indicates levels may remain elevated for a prolonged period after discontinuation. Regulatory labeling does not specify a precise timeframe for when individuals might notice changes in symptoms.


Q: Can Folison be taken with common pain relievers?

A: Regulatory documents list specific interaction warnings for prescription medications, such as certain anticonvulsants and antifolate agents. The official labeling does not include common, over-the-counter pain relievers, like ibuprofen or acetaminophen, as known interaction risks. It is important to review all medications and supplements being used with a healthcare professional.


Q: Is Folison considered safe for long-term use?

A: Studies and official information indicate that the active ingredient in Folison is an essential nutrient analog often used in a continuous, long-term administration model. However, regulatory documents also state that long-term effects are not fully established regarding the use of the product, as the follow-up durations in the most rigorous short-term trials were limited.


Q: Can Folison cause weight changes?

A: Regulatory safety documents do not list weight gain or weight loss directly as a reported adverse reaction. However, they do list gastrointestinal effects that could affect appetite, such as anorexia (loss of appetite), nausea, and abdominal distention.


Q: Is it normal to feel a bit tired when starting Folison?

A: Official regulatory safety information lists potential nervous system side effects. These include somnolence (drowsiness or sleepiness), altered sleep patterns, and transient headaches. Reported reactions in this category tend to be transient.


Q: What should I know about taking Folison if I am planning a pregnancy?

A: Official guidance emphasizes that active folate (L-methylfolate) is commonly studied and noted in official guidance as important for all women capable of becoming pregnant, including during the preconception period. The use of Folison during pregnancy is generally allowed, but the status of other deficiencies, such as Vitamin B12, must always be addressed.


Q: How is Folison classified by health regulators?

A: Folison is classified by health regulators as an Essential Nutrient Supplement or, in some cases, a Medical Food. This classification reflects its distinct role in managing metabolic deficiencies and ensuring optimal active folate levels in the body.


Q: Can Folison cause changes in mood or behavior?

A: Yes, regulatory safety documents note potential effects on mood and behavior. The label includes a caution regarding the theoretical risk of activating underlying psychiatric conditions, such as a manic state, particularly when treatment is initiated.


Q: What happens when Folison leaves the body?

A: The active ingredient in Folison, L-methylfolate, is a water-soluble substance that is primarily excreted through the kidneys. However, it is also a substance that is naturally utilized by the body and stored within certain cells, such as red blood cells.


Q: Is Folison covered by most insurance plans?

A: Official product labeling provides specific product codes that are formatted to meet the requirements of pharmacy and health insurance computer systems. This facilitates potential claim submission, but regulatory documents do not specify or guarantee coverage by individual insurance plans.


Q: Why are there different colors or shapes for Folison pills?

A: The official product labeling states that different strengths of the tablets (for example, the 7.5 mg and 15 mg strengths) are manufactured with different colors or shapes for the purpose of identification.


Q: Is Folison tested on human subjects before approval?

A: Regulatory data refers to the foundational evidence for Folison which includes short-term, randomized, placebo-controlled trials conducted in human adults. This indicates that human studies related to its safety and intended use are part of the evidence base.

How should Folison be stored and disposed of?

How to Store and Dispose of Folison?

The storage and disposal of Folison (L-Methylfolate) must strictly follow the conditions defined in official regulatory labeling to maintain product stability and safety.

Official Storage Requirements

Folison tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted temperature excursions up to 30 C. To protect the integrity of the active ingredient, the product must be protected from both light and moisture and dispensed in a tight, light-resistant container. As a mandatory safety requirement, all medication must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Folison should be discarded following official guidelines. The FDA recommends utilizing a community drug take-back program as the preferred method. If no take-back option is available, the product may be mixed with an unappealing substance (such as coffee grounds or cat litter) in a sealed bag or container and disposed of with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Folison found in:

A-Z Index: